Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying ...

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius ...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical ...

People attending a football match will be asked to sign up to a stem cell register in the hope of finding a donor for a local ...

However, leukemia originates in the bone marrow and spreads through the blood, while lymphoma originates in the spleen or lymph nodes and spreads through the lymph vessels. Leukemia and lymphoma can ...

PF-08046045 is under clinical development by Pfizer and currently in Phase I for Cutaneous T-Cell Lymphoma. According to GlobalData, Phase I drugs for Cutaneous T-Cell Lymphoma have an 84% phase ...

A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter clinical trial published in the Journal of Clinical Oncology.

Qartemi, India’s first international CAR T-cell therapy, is approved for the treatment of adult non-hodgkin lymphoma (NHL). Licensed from Hospital Clínic de Barcelona (HCB), a globally renowned ...

A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter clinical trial published in the Journal of Clinical Oncology. Cutaneous T ...

Kathryn Senior reports. Chimeric antigen receptor (CAR) T-cell therapies have proved effective in several haematological cancers including B-cell acute lymphoblastic leukaemia, diffuse large B-cell ...